發(fā)布時(shí)間：2018-05-26 20:10

  本文選題：非小細(xì)胞肺癌 + FGFR1�。� 參考：《濟(jì)南大學(xué)》2017年碩士論文

【摘要】：目的:檢測(cè)FGFR1基因在NSCLC病理組織中基因擴(kuò)增情況,研究FGFR1基因擴(kuò)增與NSCLC患者臨床特征之間的關(guān)系,為非小細(xì)胞患者的靶向治療提供理論依據(jù)。方法:采用熒光原位雜交(FISH)技術(shù)檢測(cè)147例非小細(xì)胞肺癌組織的FGFR1基因擴(kuò)增的情況,應(yīng)用SPSS 22.0統(tǒng)計(jì)軟件進(jìn)行數(shù)據(jù)處理,了解FGFR1基因擴(kuò)增的影響因素及臨床特征。結(jié)果:(1)肺鱗癌組織中FGFR1基因擴(kuò)增率為15.9%,肺腺癌組織中FGFR1基因擴(kuò)增率為5.4%,其它亞型中未發(fā)現(xiàn)FGFR1基因擴(kuò)增。肺鱗癌患者FGFR1基因擴(kuò)增率顯著高于肺腺癌患者及其他非小細(xì)胞肺癌患者,差異有統(tǒng)計(jì)學(xué)意義(p=0.026)。(2)在性別方面,FGFR1基因擴(kuò)增在男女患者中無(wú)統(tǒng)計(jì)學(xué)差異;在年齡方面,以65歲為界點(diǎn),兩組間FGFR1基因擴(kuò)增在不同年齡段的患者中無(wú)統(tǒng)計(jì)學(xué)差異;在腫瘤大小方面,以腫瘤直徑3cm為界點(diǎn),兩組間FGFR1基因擴(kuò)增在不同腫瘤直徑間無(wú)統(tǒng)計(jì)學(xué)差異;在腫瘤TNM分期方面,兩組間FGFR1基因擴(kuò)增在Ⅰ-Ⅱ期與Ⅲ-Ⅳ期不同分期的患者中亦無(wú)統(tǒng)計(jì)學(xué)差異;在外周器官轉(zhuǎn)移與否方面,兩組間FGFR1基因擴(kuò)增同樣無(wú)統(tǒng)計(jì)學(xué)差異;在吸煙與否方面,吸煙組FGFR1基因擴(kuò)增明顯高于未吸煙組,差異具有統(tǒng)計(jì)學(xué)意義。結(jié)論:(1)FGFR1基因在NSCLC中存在擴(kuò)增,肺鱗癌患者FGFR1基因擴(kuò)增率顯著高于肺腺癌及其它非小細(xì)胞肺癌類(lèi)型患者。(2)FGFR1基因擴(kuò)增與性別、年齡、腫瘤大小、TNM分期、外周器官轉(zhuǎn)移與否均無(wú)顯著無(wú)關(guān),但與患者吸煙狀況有關(guān)。(3)FGFR1基因擴(kuò)增可能成為肺鱗癌患者靶向治療中的靶點(diǎn)之一。
[Abstract]:Objective: to detect the amplification of FGFR1 gene in the pathological tissues of NSCLC, to study the relationship between the amplification of FGFR1 gene and the clinical characteristics of NSCLC patients, and to provide a theoretical basis for the targeted therapy of non-small cell patients. Methods: fluorescence in situ hybridization (fish) technique was used to detect the amplification of FGFR1 gene in 147 cases of non-small cell lung cancer (NSCLC). The data were processed by SPSS 22.0 software to understand the influencing factors and clinical characteristics of FGFR1 gene amplification. Results the amplification rate of FGFR1 gene was 15.9in lung squamous cell carcinoma, 5.4in adenocarcinoma and 5.4in lung adenocarcinoma. No amplification of FGFR1 gene was found in other subtypes. The amplification rate of FGFR1 gene in patients with lung squamous cell carcinoma was significantly higher than that in patients with lung adenocarcinoma and other non-small cell lung cancer. There was no significant difference in FGFR1 gene amplification between the two groups in different age groups; in tumor size, there was no significant difference between the two groups in tumor diameter 3cm amplification; in tumor TNM staging, there was no significant difference between the two groups. There was no significant difference in the amplification of FGFR1 gene between the two groups in different stages of stage 鈪，

本文編號(hào)：1938740